Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in ... who are either positive for the HBV surface antigen (HBsAg) or HBV core antibody ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...

Sexually transmitted ... testing for HIV antigen and antibodies was negative; a PCR assay for HIV RNA was also negative. Blood tests for hepatitis A virus IgM, hepatitis B virus core IgM ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear hepatitis ...

Background Treatment cessation in chronic HBV infection may be durable in certain patient subgroups before hepatitis B surface antigen (HBsAg) seroclearance. The role of serum HBV RNA in determining ...

Single-dose administration of E6F6 could profoundly suppress the levels of hepatitis B surface antigen (HBsAg) and HBV DNA for several weeks in HBV-transgenic mice. E6F6 regimen efficiently prevented ...

hepatitis B surface antigen; HBeAg, Hepatitis B e Antigens; anti- HBs, Anti-hepatitis B surface antigen antibody; anti-HBc, antibody to hepatitis B core antigen; anti-HBe, Hepatitis B E antibody; HBV ...

Hepatitis B surface antigen (HBsAg), core total antibody (anti-HBc) and surface antibody (anti-HBs) were detected by the Architect immunoassay (Abbott Diagnostics, Germany). Hepatitis B infection was ...

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

Patients receiving B cell-depleting agents (E.g., rituximab), chimeric antigen receptor (CAR)-T cell therapies, or cytokine/integrin inhibitors. Patients receiving tyrosine kinase inhibitor (TKI ...